Characterisation of asthma that develops during adolescence; findings from the Isle of Wight Birth Cohort  by Kurukulaaratchy, Ramesh J. et al.
Respiratory Medicine (2012) 106, 329e337Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedCharacterisation of asthma that develops during
adolescence; findings from the Isle of Wight Birth
CohortRamesh J. Kurukulaaratchy a,b, Abid Raza a, Martha Scott a, Paula Williams a,
Susan Ewart c, Sharon Matthews a, Graham Roberts a,b,d, S. Hasan Arshad a,b,*aThe David Hide Asthma and Allergy Research Centre, St Mary’s Hospital, Newport, Isle of Wight, PO30 5TG,
United Kingdom
bRespiratory Biomedical Research Unit, University of Southampton Faculty of Medicine, Southampton, SO16 6YD,
United Kingdom
c Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, USA
dHuman Development and Health, University of Southampton Faculty of Medicine, Southampton, SO16 6YD,
United Kingdom
Received 15 September 2011; accepted 12 December 2011
Available online 31 December 2011KEYWORDS
Adolescence;
Asthma;
Atopy;
Bronchial hyper-
responsiveness;
Rhinitis;
ParacetamolAbbreviations: ANOVA, Analysis of var
slope; FeNO, Fractional exhaled nitric
litres) in 1 s; FVC, Forced vital capaci
prick test.
* Corresponding author. The David H
Kingdom. Tel.: þ44 01983534373; fax
E-mail addresses: ramesh.kurukul
hotmail.com (M. Scott), paula.willia
(S. Matthews), g.c.roberts@soton.ac.
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2011.12.006Summary
Background: Understanding of adolescent-onset asthma remains limited. We sought to charac-
terise this state and identify associated factors within a longitudinal birth cohort study.
Methods: The Isle of Wight Whole Population Birth Cohort was recruited in 1989 (NZ 1456) and
characterised at 1, 2, 4, 10 and 18-years. “Adolescent-onset asthma” was defined as asthma at
age 18 without prior history of asthma, “persistent-adolescent asthma” as asthma at both 10
and 18 and “never-asthma” as those without asthma at any assessment.
Results: Adolescent-onset asthma accounted for 28.3% of asthma at 18-years and was of
similar severity to persistent-adolescent asthma. Adolescent-onset asthmatics showed
elevated bronchial hyper-responsiveness (BHR) and atopy at 10 and 18 years. BHR in this group
at 10 was intermediate to that of never-asthmatics and persistent-adolescent asthma. By 18
their BHR, bronchodilator reversibility and sputum eosinophilia was greater than never-iance; BHR, Bronchial hyper-responsiveness; BDR, Bronchodilator reversibility; DRS, Doseeresponse
oxide; FEF25e75, Forced expiratory flow 25e75% (in litres/second); FEV1, Forced expiratory volume (in
ty (in litres); GLM, General linear models; NSAIDs, Non-steroidal anti-inflammatory drugs; SPT, skin
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330 R.J. Kurukulaaratchy et al.Table 1 Mode of participation i
How visit/questionnaire took plac
In person
By telephone
By post
Total (N )
a n, Number of participants in eac
b Chi-square test for difference beasthmatics and comparable to persistent-adolescent asthma. At 10, males who later developed
adolescent-onset asthma had reduced FEV1 and FEF25e75, while females had normal lung func-
tion but then developed impaired FEV1 and FEF25e75 in parallel with adolescent asthma.
Factors independently associated with adolescent-onset asthma included atopy at 10
(ORZ 2.35; 95% CIZ 1.08e5.09), BHR at 10 (3.42; 1.55e7.59), rhinitis at 10 (2.35; 1.11
e5.01) and paracetamol use at 18-years (1.10; 1.01e1.19).
Conclusions: Adolescent-onset asthma is associated with significant morbidity. Predisposing
factors are atopy, rhinitis and BHR at age 10 while adolescent paracetamol use is also associ-
ated with this state. Awareness of potentially modifiable influences may offer avenues for miti-
gating this disease state.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Several longitudinal cohort studies have investigated the
natural history of asthma from birth into adulthood. A
consensus has arisen from such work that most adult
asthma originally develops in childhood.1e3 However, adult
asthma is now recognised to be a heterogeneous collection
of diverse phenotypes.4 In turn, awareness has grown that
some adult asthma first appears in adolescence or early
adulthood.5 Understanding of adolescent or early adult-
onset asthma is still evolving and characterisation of such
disease remains incomplete. Associations with female
predominance and non-atopic status have been
described.6e8 Potentially relevant early life risk factors for
adolescent onset asthma are emerging. Pre-existing rhinitis
has been implicated as a risk factor for subsequent child-
hood,9 adolescent10 and adult10,11 wheeze/asthma. Rhinitis
is a risk factor for bronchial hyper-responsiveness (BHR). A
substantial proportion of children have been demonstrated
to have asymptomatic BHR.12 Asymptomatic BHR may be
another risk factor for subsequent asthma develop-
ment5,13,14 as may lower childhood lung function.5
Adolescence is a period of dynamic physiological
changes that may influence development of new-onset
asthma. So too might behavioural changes that lead to
harmful exposures during adolescence. Thus tobacco
smoke15,16 and other less obvious exposures like para-
cetamol may be important.17 Here we characterised
adolescent-onset asthma in the Isle of Wight Birth Cohort,
identifying relevant risk factors for its development.
Methods
An unselected whole population birth cohort (nZ 1456)
was established in 1989 on the Isle of Wight, UK to study then 18-year study follow-up.
e Overall % (n)a
66 (864)
32 (421)
2 (28)
100 (1313)
h group with (%)Z percentage gi
tween males and females with sinatural history of asthma with subsequent assessment at 1,
2, 4, 10 and 18-years. Methodology for the first decade of
follow-up has been published previously.18e20
The Local Research Ethics Committee (06/Q1701/34)
approved follow-up at 18 years. Both study-specific and
International Study of Asthma and Allergies in Childhood
(ISAAC)21 questionnaires were used to obtain information
on disease plus relevant associated factors such as
domestic pet exposure, reported passive and personal
tobacco exposures, and family history of disease. Details of
key questions are provided under definitions with further
important questions listed in the online supplement. Self-
rated health status was recorded by Visual Analogue Scale
(VAS) from the European Quality of Life 5-Dimensional tool
(EQ-5D).22 Participation was in person, by telephone or by
post; the proportions followed through each modality are
given in Table 1. Participants attending in person under-
went spirometry, fractional exhaled nitric oxide (FeNO)
measurement, bronchodilator reversibility (BDR) to 600 mg
inhaled salbutamol, methacholine challenge test and skin
prick test (SPT). Identical methods, published previously,20
were used for spirometry and challenge testing at 10 and 18
years. FeNO (Niox mino, Aerocrine AB, Solna, Sweden) and
SPT to common food/aeroallergens (ALK-Abello, Horsholm,
Denmark) were performed as reported previously.23 Brief
details of testing methodology are provided in the
Supplementary material. At 18 years a subgroup of asth-
matics and controls (without asthma) attended separately
for sputum induction using a standard protocol.24 If Forced
Expiratory Volume in 1 s (FEV1) was 60% predicted,
participants received serial nebulisation of hypertonic
saline (4.5%) for 5 min at a time to a maximum of 20 min.
Samples were immediately placed on ice and processed
within 2 h for cytology. Total and differential cell counts
were recorded. A 3% eosinophil count cut-off defined
significant eosinophilia.Male % (n)a Female % (n)a p-Valueb
63 (410) 69 (454) 0.04
35 (231) 29 (190) 0.006
2 (12) 2 (16) 0.42
100 (653) 100 (660) 0.82
ven for each group total represented by N.
gnificance at p< 0.05.
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Asthma was defined as “yes” to “have you ever had
asthma?” and either of “have you had wheezing in the last
12 months”? or “have you had asthma treatment in the last
12 months?”. “Adolescent-onset asthma” was defined as
having asthma at age 18 but no prior history of asthma,
“persistent-adolescent asthma” as having asthma at both
10 and 18 with “never-asthma” applied to those not
reporting asthma at any study assessment. A small group
(NZ 17) was identified with “recurrence of childhood
asthma” who had asthma in the first 4-years of life, not at
10 but had it again at 18-years. Rhinitis was defined by
“yes” to “have you ever had a problem with sneezing, runny
or blocked nose in the absence of cold or flu?” plus “have
you had symptoms in the last 12 months?” Atopy was
defined by positive SPT (mean wheal diameter 3 mm
greater than negative control) to at least one allergen.Statistical methods
Data were entered onto SPSS (version 17). Categorical
variables were assessed by Chi-square tests. For normally
distributed continuous measures, independent samples t-
tests were applied. For multiple comparisons, one-way
analysis of variance (ANOVA) with Bonferroni correction
was used. For non-normally distributed data, Man-
neWhitney U test and KruskaleWallis ANOVA were applied.
General Linear Models were used to compare height
adjusted lung function differences.
Bronchial hyper-responsiveness (BHR) was determined
by methacholine concentration causing a 20% fall in FEV1
from the post-saline value, expressed as PC20 with a posi-
tive test defined by PC20< 8 mg/ml. A continuous dos-
eeresponse slope (DRS) measure of BHR was also estimated
by least-square regression of percentage change in FEV1
upon cumulative methacholine dose for each child. The DRS
obtained was transformed as Log10 (DRSþ 10), to satisfy
normality and homoscedasticity. Higher values inferred
greater BHR.
At 18 years, study participants reported average
monthly use of paracetamol and NSAID (non-steroidal anti-Table 2 Symptoms, treatment, healthcare utilisation and qualit
at 18-years.
Symptoms Adolescent onset
asthma % (n/N )
Wheeze frequency >4 episodes/year 30 (17/56)
Exercise induced wheeze 64 (36/56)
Sleep disturbed by wheeze in past year 45 (25/56)
Sleep disturbed >1 time per week 13 (7/56)
Speech disturbed by asthma in past year 14 (8/56)
Nocturnal cough in past year 32 (18/56)
Current asthma treatment 80 (45/56)
Ever attended A&E with asthma 11 (5/44)
Ever hospitalised with asthma 7 (3/44)
Comparisons in this table were made using Chi-square test, with signifi
participants with condition; N, total number of participants that res
Department.inflammatory drug) during the past year. Since consumption
of these drugs was not normally distributed in our pop-
ulation, data are presented as median values with 25th to
75th centiles.
To identify risk factors for adolescent-onset asthma,
univariate risk analysis was performed against non-
wheezers. Factors demonstrating trends for univariate
significance (p< 0.1) were entered en-bloc into logistic
regression models to identify independently significant risk
factors.Results
High cohort follow-up was maintained at 10-years (94.3%;
1373/1456) and 18 years (90.2%; 1313). Those attending the
Centre for full data collection at 18 years (NZ 864) did not
differ in key characteristics from the overall study pop-
ulation at 18 years, although attendees were significantly
more likely to be in fulltime education (Table E1; Online
Supplement).
Asthmaprevalence rose from14.7% (201/1368) at 10 years
to 17.9% (234/1306) at 18 years. Of asthmatics at 18 years
who also had data at 10 years, 63.1% (125/198) had
persistent-adolescent asthma, 28.3% (56/198) had
adolescent-onset asthma and 8.6% (17/198) recurrence of
earlier childhood asthma. In terms of incidence, adolescent-
onset asthma arose in 9.2% (56/611) of those without asthma
at 10-years, with non-significant trends to female predomi-
nance (maleZ 6.9% versus femaleZ 11.7%; pZ 0.06).
At 18 years, adolescent-onset asthma was comparable to
persistent-adolescent asthma in current disease severity and
secondary healthcare use (Table 2). However, self-rated
health status was significantly greater in adolescent-onset
asthmatics (80.27 versus 74.37; mean differenceZ 5.90;
pZ 0.035; where lower scores infer lower health status).
Prescription of anti-asthma treatment was also greater in
adolescent-onset than persistent-adolescent asthma.
Significant differences were observed for height and
weight by gender in the 10- to 18-year period. At 10 years,
females were heavier than (36 versus 34 kg; p< 0.0001),
but of comparable height (139 versus 139 cm; pZ 0.97) to
males. By 18 years males were significantly taller (178y of life in adolescent-onset and persistent-adolescent asthma
Persistent
asthma % (n/N )
Odds ratio 95% Confidence
interval
p-Value
34 (42/124) 0.85 0.43e1.67 0.64
77 (96/124) 0.53 0.27e1.04 0.07
50 (60/120) 0.81 0.43e1.52 0.51
17 (20/120) 0.71 0.29e1.77 0.48
18 (22/120) 0.74 0.31e1.76 0.51
45 (55/123) 0.59 0.30e1.13 0.11
66 (79/120) 2.12 1.00e4.48 0.05
17 (14/79) 0.60 0.21e1.72 0.44
14 (11/79) 0.45 0.13e1.61 0.38
cance at p< 0.05 % (n/N )[ percentage, where n is the number of
ponded in that group; A&E, Accident and Emergency or Casualty
332 R.J. Kurukulaaratchy et al.versus 165 cm; p< 0.001) and heavier (71 versus 65 kg;
p< 0.001) than females. When differences in height,
weight and Body Mass Index were compared between
adolescent-onset and never-asthmatics, no significant
differences were observed at 10 or 18 years (Table E2;
Online Supplement). Since males and females showed
differential somatic growth over adolescence, analysis of
differences in lung function between adolescent-onset and
never-asthmatics at 10 and 18 years were stratified by
gender (Tables 3a and 3b). At 10, male adolescent-onset
asthmatics had significantly greater airflow obstruction
(lower FEV1, FEF25e75% and FEV1/FVC ratio) than male
never-asthmatics (Table 3a). No significant difference
between male adolescent-onset and never-asthmatics was
seen for gain in lung function from 10 to 18 years. By 18,
significant differences in lung function among males had
disappeared. Lung function analysis in females (Table 3b)
showed no significant difference between adolescent-onset
and never-asthmatics at 10 years. Female adolescent-onset
asthmatics demonstrated lower gain in FEV1 than never-
asthmatics between 10 and 18 years. At 18, female
adolescent-onset asthmatics had significantly lower FEV1
and FEF25e75% than female never-asthmatics.
Atopy did not differ significantly between the
adolescent-onset and never-asthmatics at 4-years but was
significantly higher in adolescent-onset asthmatics at 10
and 18 years (Table 4). Significant allergen sensitivities in
this regard were grass (16% versus 9%; pZ 0.02) plus tree
pollen (6% versus 1%; pZ 0.04) at 10-years and house dust
mite (49% versus 21%; p< 0.001), dog (21% versus 6%;
pZ 0.001), cat (15% versus 7%; pZ 0.04) and tree pollen
(13% versus 4%; pZ 0.02) at 18. BHR was greater in
adolescent-onset asthma than never-asthma (p< 0.001) at
10 and 18 years (Table 4).Table 3a Comparison of pulmonary function at age 10 and 18 y
Adolescent onset
asthma (nZ 15)
Never as
(nZ 171
Spirometry at 18 yearsa
FEV1 (L) (S.E.) 4.55 (0.14) 4.70 (
FVC (L) (S.E.) 5.41 (0.15) 5.37 (
FEV1/FVC (S.E.) 0.84 (0.02) 0.88 (
FEF25e75% (L/s) (S.E.) 4.69 (0.28) 5.18 (
Spirometry at 10 yearsa
FEV1 (L) (S.E.) 1.97 (0.06) 2.11 (
FVC (L) (S.E.) 2.36 (0.06) 2.39 (
FEV1/FVC (S.E.) 0.83 (1.40) 0.89 (
FEF25e75% (L/s) (S.E.) 2.10 (0.14) 2.49 (
Gain in spirometry from 10 to 18 yearsa
FEV1 (L) (S.E.) 2.54 (0.12) 2.60 (
FVC (L) (S.E.) 3.01 (0.13) 2.98 (
FEV1/FVC (S.E.) 0.008 (0.02) 0.009 (
FEF25e75% (L/s) (S.E.) 2.43 (0.21) 2.69 (
n, Number of participants who provided information; FEV1, forced e
(S.E.); FVC, forced vital capacity in litres (L) with standard error (S.E.)
25e75% in litres per second (L/s) with standard error (S.E.).
a General Linear Model (GLM) for the difference (b) between adole
level of p< 0.05 with 95% confidence intervals. Estimated marginal
means.At 10 years, analysis of DRS showed that adolescent-
onset asthmatics had intermediate BHR, significantly less
than for persistent-adolescent asthma but significantly
greater than for never e asthma (Figure 1a). Intermediate
BHR DRS was retained at 18-years though by then there was
no significant difference in DRS between adolescent-onset
and persistent-adolescent asthma (Figure 1b). At 18-years
adolescent-onset asthmatics had significantly greater BDR
and FeNO than never-asthmatics. Among those undergoing
sputum induction, 11 of 12 (92%) adolescent-onset asth-
matics were atopic, while only 12 of 30 never-asthmatics
were atopic at 18 years (pZ 0.002). Adolescent-onset
asthmatics had higher sputum eosinophil counts than
never-asthmatics and greater prevalence of significant
(>3%) sputum eosinophilia (Table 5).
Univariate analysis of potential associated factors (Table
E3; Online data supplement) identified atopy at 10 and 18
years, rhinitis at 10 and 18 years, BHR at 10 and 18 years,
maternal history of asthma, and paracetamol use at 18 as
having significant association with adolescent-onset
asthma. A backward stepwise multiple logistic regression
model created using all factors with univariate trends for
significance (p< 0.1) found independently significant asso-
ciation for adolescent-onset asthma with atopy, rhinitis and
BHR at age 10-years plus paracetamol consumption at 18
(Table 6).Discussion
Adolescent-onset asthma developed in 9% of those without
asthma at 10 years. It constituted over 25% of asthma at 18
years when it showed similar phenotypic characteristics,
disease severity and morbidity to persistent-adolescentears between adolescent-onset and never-asthmatic males.
thma
)
b 95% Confidence
interval
p-Value
0.04) 0.16 0.46 to 0.14 0.29
0.05) 0.04 0.28 to 0.36 0.80
0.005) 0.03 0.002 to 0.001 0.07
0.08) 0.49 1.06 to 0.09 0.10
0.02) 0.14 0.26 to e0.02 0.03
0.02) 0.03 0.15 to 0.10 0.70
0.42) 0.05 0.08 to e0.02 0.001
0.04) 0.40 0.68 to e0.11 0.006
0.03) 0.51 0.29 to 0.19 0.67
0.04) 0.03 0.23 to 0.30 0.81
0.005) 0.02 0.01 to 0.05 0.27
0.06) 0.26 0.70 to 0.18 0.25
xpiratory volume in first second in litres (L) with standard error
; FEV1/FVC, ratio of FEV1 to FVC; FEF25e75%, forced expiratory flow
scent-onset asthma to never-asthma group determined at alpha
means used for determination of height adjusted lung function
Table 3b Comparison of pulmonary function at age 10 and 18 years between adolescent-onset and never-asthmatic females.
Adolescent onset
asthma (nZ 19)
Never asthma
(nZ 213)
b 95% Confidence
interval
p-Value
Spirometry at 18 yearsa
FEV1 (L) (S.E.) 3.33 (0.09) 3.53 (0.03) 0.20 0.38 to 0.02 0.03
FVC (L) (S.E.) 3.85 (0.10) 3.99 (0.03) 0.014 0.35 to 0.07 0.19
FEV1/FVC (S.E.) 0.86 (0.02) 0.89 (0.004) 0.026 0.06 to 0.005 0.10
FEF25e75% (L/s) (S.E.) 3.69 (0.20) 4.09 (0.06) 0.42 0.82 to e0.02 0.04
Spirometry at 10 yearsa
FEV1 (L) (S.E.) 1.96 (0.05) 2.02 (0.01) 0.06 0.15 to 0.04 0.25
FVC (L) (S.E.) 2.20 (0.05) 2.25 (0.01) 0.05 0.15 to 0.05 0.34
FEV1/FVC (S.E.) 0.89 (1.25) 0.90 (0.37) 0.35 0.02 to 0.02 0.79
FEF25e75% (L/s) (S.E.) 2.41 (0.12) 2.54 (0.04) 0.13 0.38 to 0.12 0.30
Gain in spirometry from 10 to 18 yearsa
FEV1 (L) (S.E.) 1.36 (0.07) 1.52 (0.02) 0.16 0.31 to e0.006 0.04
FVC (L) (S.E.) 1.62 (0.09) 1.74 (0.03) 0.13 0.31 to 0.05 0.16
FEV1/FVC (S.E.) 0.03 (0.02) 0.01 (0.01) 0.02 0.05 to 0.01 0.26
FEF25e75% (L/s) (S.E.) 1.27 (0.16) 1.55 (0.05) 0.2 0.61 to 0.05 0.10
n, Number of participants who provided information; FEV1, forced expiratory volume in first second in litres (L) with standard error
(S.E.); FVC, forced vital capacity in litres (L) with standard error (S.E.); FEV1/FVC, ratio of FEV1 to FVC; FEF25e75%, forced expiratory flow
25e75% in litres per second (L/s) with standard error (S.E.).
a General Linear Model (GLM) for the difference (b) between adolescent onset asthma to never asthma group determined at alpha level
of p< 0.05 with 95% confidence intervals. Estimated marginal means used for determination of height adjusted lung function means.
Adolescent onset asthma 333asthma that commenced in the first decade of life. Atopy,
rhinitis and presence of BHR at 10 years predicted subse-
quent development of adolescent-onset asthma. Among the
environmental factors, only paracetamol use at age 18
years showed independently significant association with
adolescent-onset asthma.
The early-adult newly diagnosed asthma characterised
in the Tucson cohort5 bears some similarity to the
adolescent-onset asthma identified in the present study.
Our prevalence of adolescent-onset asthma (28%) is
comparable to that of early adult newly diagnosed asthma
in the Tucson cohort (27%). However, they found a signifi-
cant female predominance (71%) for incident asthma inTable 4 Comparison of Atopy, BHR, BDR and FeNO between ad
Adolescent onset asthma Neve
Atopy at 4% (n/N ) 19 (9/48) 13
Atopy at 10% (n/N ) 42 (21/50) 18
Atopy at 18% (n/N ) 64 (25/39) 34
BHRa at 10% (n/N ) 52 (22/42) 20
BHR slopeb at 10 (S.E.) 1.66 (0.08) 1.34
BHRa at 18% (n/N ) 25 (7/28) 2
BHR slope at 18b (n) (S.E.) 1.32 (28) (0.08) 1.06
BDR at 18c % (n) (S.E.) 7.80 (35) (1.20) 4.05
Geometric mean FeNOd at 18
(n) (S.E.)
29 (25) (1.15) 19
Odds ratio of adolescent onset asthma to never asthma at univariate le
S.E., standard error of mean.
a BHR %, proportion with PC20 less than 8 mg/ml (n/N ).
b BHR slope, a high value represents increased bronchial reactivity
slope (DRS).
c BDR %, relative percent FEV1 bronchodilator reversibility response
d Geometric mean FeNO value (ppb or parts per billion).early adulthood. That is consistent with significant female
predominance of new-onset adolescent asthma in studies
from New Zealand,6 Norway,7 and Germany.8 Recent find-
ings from the Netherlands,25 while showing no significant
gender difference in asthma prevalence at 16 years,
showed greater adolescent incident asthma and less
adolescent asthma remission in females. Although we found
higher female prevalence of adolescent-onset asthma
(60.7%), that did not reach statistical significance. Another
notable distinction is that we found significant association
of adolescent-onset asthma with atopy at 10 and 18 years
whereas prior studies6e8 mainly identified a non-atopic
state.olescent-onset and never-asthma.
r asthma Odds ratio 95% Confidence interval p-Value
(67/519) 1.56 0.72e3.36 0.26
(89/505) 3.39 1.85e6.21 <0.001
(153/452) 3.49 1.76e6.91 <0.001
(65/332) 4.52 2.33e8.77 <0.001
(0.02) 5.41 2.68e10.93 <0.001
(7/312) 14.52 4.66e45.28 <0.001
(312) (0.01) 8.48 2.84e25.27 <0.001
(427) (0.24) 1.12 1.05e1.18 <0.001
(292) (1.05) 7.37 2.08e26.12 0.002
vel determined by logistic regression with significance at p< 0.05.
; obtained by log10 (DRSþ 10) transformation of doseeresponse
following administration of 600 mcg of salbutamol.
Figure 1 (a) Bronchial reactivity (doseeresponse slope) at 10 years in adolescent asthma groups P-values calculated by
comparison of Log10 (doseeresponse slope þ10), using ANOVA with post-hoc Bonferroni correction. Never asthmaZ 331,
adolescent onsetZ 42, persistent asthmaZ 105. (b) Bronchial reactivity (doseeresponse slope) at 18 years in adolescent asthma
groups P-values calculated by comparison of Log10 (doseeresponse slopeþ 10), using ANOVA with post-hoc Bonferroni correction.
Never asthmaZ 312, Adolescent onsetZ 28, Persistent asthmaZ 67.
Table 5 Sputum characteristics of adolescent-onset and never-asthmatics at 18 years.
Induced sputum Adolescent onset
asthmaa (NZ 12)
Never asthma
(NZ 30)
Odds ratio 95% Confidence
interval
p-Value
Eosinophilsb (%), median (IQR) 2.4 (5.8) 0.3 (1.3) 1.35 1.02e1.78 0.02
Eosinophils > 3% % (n/N ) 50 (6/12) 13 (4/30) 6.50 1.46e29.05 0.01
Neutrophils b (%), median (IQR) 11 (22) 12 (35) 0.98 0.95e1.01 0.22
Epithelial cellsb (%), median
(IQR)
6 (13) 4.5 (9) 1.01 0.95e1.08 0.34
a Odds ratio of adolescent onset asthma to never asthma at univariate level determined by logistic regression with significance at
p< 0.05.
b Median values of percent cells reported for eosinophil, neutrophil and epithelial cells with (IQR) inter-quartile range.
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Table 6 Multivariate analysis of factors associated with adolescent onset asthma.
Odds ratio 95% Confidence interval p-Value
Paracetamol at 18 1.10 1.01 1.19 0.027
Atopic at 10 years 2.35 1.08 5.09 0.031
Rhinitis at 10 years 2.35 1.11 5.01 0.027
Bronchial reactivity at 10 3.42 1.55 7.59 0.002
Odds ratio for adolescent onset asthma to never asthma determined by backward stepwise multivariate logistic regression with
significance at p< 0.05. All factors showing univariate trends for significance (p< 0.1) were included in the regression model along with
gender. The factors included in the model were; gender, atopy at 10, rhinitis at 10, maternal asthma, social class IeIII at birth, par-
acetamol use at 18, and proportion with BHR at 10.
Adolescent onset asthma 335We recently reported a considerable rise in rhinitis
prevalence over adolescence (from 22.6% at 10 years to
35.8% at 18 years) in our cohort with predominant incident
atopic rhinitis in males and non-atopic rhinitis in females
during this period.26 Rhinitis at 10 years emerged as inde-
pendently significant for adolescent-onset asthma in the
present study. Prior studies have highlighted rhinitis as
a risk factor for subsequent wheeze/asthma. Rochat9 re-
ported a Relative Risk [RR] of 3.82 for preschool rhinitis
with regard to developing wheeze between 5 and 13 years
while Burgess10 found that childhood rhinitis increased
adolescent asthma risk 4-fold and that of adult asthma 2-
fold. These relationships have been demonstrated in adult
populations too. Shaaban11 reported RR of 3.53 for adult
rhinitis in relation to later asthma. Rhinitis has also been
identified as a risk factor for subsequent BHR.27 Such results
support the “one airway, one disease” concept linking
upper and lower airways diseases.28
We previously reported12 substantial asymptomatic BHR
at 10 years, which we now show is a significant risk factor
for adolescent-onset asthma. While BHR declined across all
groupings during adolescence in our study, the BHR dos-
eeresponse slope for adolescent-onset asthmatics shifted
during adolescence towards the greater levels of
persistent-adolescent asthmatics. Asymptomatic BHR has
been linked to enhanced airway inflammation and remod-
elling,13 accelerated decline in FEV1
14 and subsequent
asthma.29 Laprise13 demonstrated that airway changes in
subjects with asymptomatic BHR became more exaggerated
once symptoms develop. We found significant sputum
eosinophilia and raised FeNO in our adolescent-onset
asthmatics at 18 years, indicating that symptoms, BHR
and airway inflammation go hand in hand in this group.
Stern et al.5 demonstrated associations in the Tucson
cohort between newly diagnosed adult asthma at 22 years
and BHR/impaired lung function at 6 years. We found that
at 10 years, male adolescent-onset asthmatics had
evidence of impaired lung function while pre-symptomatic.
This may reflect more pronounced effects of subclinical
disease on lung function in males at that age on account of
naturally smaller relative airway calibre in preadolescent
males who have yet to enter their growth spurt. By
contrast, we detected reduced lung function in female (but
not male) adolescent-onset asthmatics at 18 years. These
findings need to be interpreted with caution given the small
sample sizes involved. However, if replicated elsewhere,
the cause of such gender differences are worthy of specu-
lation. Females have a shorter period of adolescent growththat stops at menarche while male growth continues
longer.30 Thus, continuing adolescent male growth might
allow male lung function to “outpace” effects of disease.
Female lung function could be more vulnerable to impair-
ment by adolescent-onset asthma as they attain maximal
growth earlier and their lung function cannot “escape” the
impact of ongoing disease.
The only adolescent factor significantly associated with
adolescent-onset asthma was paracetamol use at 18. The
role of paracetamol as a risk factor for asthma via enhanced
oxidative airway damage is gaining increasing scrutiny.17,31
However it is worth noting that we did not detect any
association of other potent oxidative effects such as
tobacco smoke with adolescent-onset asthma which may
cast doubt over that mechanism as an explanation for any
relationship with paracetamol. We did not adopt categor-
ical cut-offs to define paracetamol consumption as there is
no clear evidence of clinically relevant cut-offs in that
context. A limitation of our study is lack of precise data on
dosage and indication for use of paracetamol. Therefore
these findings should be viewed as demonstrating an asso-
ciation rather than causative relationship. Confounding by
indication cannot be excluded and reverse causation
remains a potential explanation of our reported association
of paracetamol exposure with adolescent-onset asthma.
We did not identify evidence of early-life environment
predisposing to adolescent-onset asthma. By contrast
tobacco exposures, in early life and adolescence, have
previously been implicated as risk factors for incident
airways disease.15,16,32 However smoking-related incident
disease may reflect various wheezing phenotypes not all of
which receive an asthma diagnosis. We also did not find
associations between adolescent-onset asthma and other
previously frequently reported asthma risk factors such as
family history of asthma/allergy. This may reflect that
heredity is more significant for some asthma phenotypes
than others.
Our study has several strengths. The prospective nature
of our work enables better accuracy in assessing temporal
relationships and risk factors. Recall bias maybe problem-
atic in longitudinal studies of disease development.
However, the high rate of cohort follow-up strengthens the
reliability of our findings. We used standardised study
materials including ISAAC questionnaires, validated in
diverse populations, to ensure comparability with other
populations. Although asthma definitions were based on
questionnaire responses, we further obtained a range of
objective measurements including SPT, spirometry, BDR,
336 R.J. Kurukulaaratchy et al.FeNO, induced sputum and BHR to validate those. We
defined adolescent-onset asthma as that absent at 10 years
but present at 18 years. One potential concern is whether
this overestimated adolescent-onset asthma by including
asthma that had existed in earlier childhood but was not
present at age 10. To counter this we excluded 17 cases of
recurrent childhood asthma in adolescence. The remaining
56 cases of adolescent-onset asthma had no evidence of
earlier childhood asthma from prospectively collected
data. We did not exclude 17 cases with isolated episodes of
wheezing in the first few years of life, as early life wheezing
may not represent asthma. It is impossible to exclude a few
cases of disease recurrence amongst incident asthma in our
study, though as cited by the Tucson group in a similar
study5 we can be confident that all our incident asthma
cases represent first expression of disease severe enough to
obtain an asthma diagnosis. Another potential limitation of
our study is the fact that few subjects had “complete” data
that included all supporting objective tests. Against that
criticism though, subjects on which major conclusions are
based, all had “core” questionnaire data.
An important implication of our characterisation of
adolescent-onset asthma is that we identified potentially
modifiable risk factors, present at a pre-symptomatic
stage. Treatment of childhood rhinitis, with anti-
inflammatory drugs or allergen specific immunotherapy
might offer an avenue to reduce adolescent-onset asthma.
Evidence to support that notion is limited but one obser-
vational study27 noted remission of asymptomatic BHR
when rhinitis was treated with nasal steroids. Immuno-
therapy has been shown to reduce asthma in children with
allergic rhinitis33 and may prove beneficial in reducing
adolescent-onset asthma risk in such children.
In conclusion, adolescent-onset asthma is associated
with pre-existing atopy, rhinitis and asymptomatic BHR
plus adolescent behaviour such as paracetamol use.
Awareness of potentially modifiable influences may
reduce the impact of this disease state and should stim-
ulate future work.
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